Show simple item record

dc.contributor.authorPerez, O
dc.contributor.authorBracho, G
dc.contributor.authorLastre, M
dc.contributor.authorMora, N
dc.contributor.authorDel Campo, J
dc.contributor.authorGil, D
dc.contributor.authorZayas, C
dc.contributor.authorAcevedo, R
dc.contributor.authorGonzalez, D
dc.contributor.authorLopez, JA
dc.contributor.authorTaboada, C
dc.contributor.authorSolis, RL
dc.date.accessioned2017-05-03T16:58:39Z
dc.date.available2017-05-03T16:58:39Z
dc.date.issued2004
dc.date.modified2009-12-21T06:45:39Z
dc.identifier.issn0818-9641
dc.identifier.doi10.1111/j.1440-1711.2004.01293.x
dc.identifier.urihttp://hdl.handle.net/10072/27867
dc.description.abstractProteoliposomes (PL) from Neisseria meningitidis B have been widely used as a core antigen for antimeningococcal vaccination. PL contain major outer membrane proteins, LPS and phospholipids, and they induce a strong Th1 immune response, but they have low stability in solution. Attending to the need for new vaccine adjuvants, we developed a highly stable cochleate structure (CS) from PL using a technology that allows easy incorporation of new antigens. We explored the ability of PLCS to activate the immune system and its possible application as an adjuvant for parenteral and mucosal routes. Our results showed that PLCS were able to upregulate the expression of MHC class II and costimulatory molecules on human dendritic cells, as well as being able to stimulate the production of soluble mediators of a Th1 response, such as IL-12 and nitric oxide. High levels of anti-PL IgG were detected in serum after i.m. or mucosal (oral and nasal) administration, but also anti-PL secretory IgA was produced in saliva following nasal delivery. The immune response polarization to a Th1 pattern was confirmed by the induction of IgG2a antibodies, positive delayed type hypersensitivity reactions, and IFN-? production by splenocytes from immunized mice. The adjuvant potential was explored using PLCS containing ovalbumin (Ova). PLCS-Ova was able to elicit a substantial increase in anti-Ova IgG compared with Ova alone. In addition, a significant reduction in lesion size was observed in mice immunized with Leishmania major antigens in PLCS after challenge with virulent protozoa, suggesting at least partial modulation of the Th2 environment induced by this parasite. In conclusion, our results support the use of PLCS as a potent Th1 adjuvant for parenteral and mucosal vaccines.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherAustralasian Society for Immunology
dc.publisher.placeAustralia
dc.relation.ispartofpagefrom603
dc.relation.ispartofpageto610
dc.relation.ispartofissue6
dc.relation.ispartofjournalImmunology and Cell Biology
dc.relation.ispartofvolume82
dc.subject.fieldofresearchBiochemistry and cell biology
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchImmunology not elsewhere classified
dc.subject.fieldofresearchcode3101
dc.subject.fieldofresearchcode3204
dc.subject.fieldofresearchcode320499
dc.titleNovel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2004
gro.hasfulltextNo Full Text
gro.griffith.authorLopez Ramirez, Alejandro


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record